The key facts

  • KCL-286 selectively activates the retinoic acid receptor RARβ and was developed as part of spinal cord injury research
  • After treatment, the Tg2576 mice showed fewer DNA breaks and fewer signs of neuroinflammation
  • The drug has passed a phase one safety trial in humans but has not been tested for efficacy in Alzheimer's disease

Results in a mouse model

Scientists at King's College London have published in the journal FEBS Open Bio the results of testing the experimental drug KCL-286 in genetically modified Tg2576 mice, used as a model of Alzheimer's disease. According to Gazeta.Ru, after treatment there were fewer signs of neuronal DNA damage, and signs of neuroinflammation also decreased: the shape of microglial cells and astrocytes became closer to normal, which is consistent with a reduction in their pathological activation.

How the substance works

KCL-286 was developed as part of spinal cord injury research and selectively activates the retinoic acid receptor RARβ, a participant in a signaling pathway associated with vitamin A derivatives. One of its targets was double-strand DNA breaks — damage in which both strands of the molecule are disrupted. Their accumulation in neurons is considered one of the early processes linked to Alzheimer's disease. The authors partly attribute the enhanced repair to increased activity of the repair factor BRCA1.

What has already been tested in humans and what lies ahead

KCL-286 has already passed a phase one trial of safety and tolerability in humans as part of a previous development program. However, this was not a test of efficacy in Alzheimer's disease — that would require separate clinical studies. The authors emphasize that the observed changes do not yet prove the drug can halt dementia or improve memory in humans. The approach is notable for targeting several cellular processes involved in the disease at once, but the path from mouse models to a validated therapy remains long.